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quality-adjusted life years (QALYs) were calculated from utility data sourced from 
the published literature. The cost-effectiveness was reported as an incremental 
cost-effectiveness ratio (ICER). To assess uncertainty, univariate deterministic and 
multivariate probabilistic sensitivity analyses (PSA) were performed. Results: 
Compared to the DPP4i class, dapagliflozin was associated with 0.023 incremental 
QALYs (95% CI: -0.058, 0.105), at an additional cost of £253 (95% CI: -£302, £741). This 
resulted in an ICER of £10,995 per QALY gained. The incremental cost associated with 
dapagliflozin was primarily due to the additional drug acquisition cost, whereas the 
QALY gain estimated was associated with superior weight reduction and its impact 
on health-related quality of life for dapagliflozin relative to the DPP4i’s. Univariate 
analyses demonstrated that the ICER was most sensitive to varying the weight 
change parameter for the comparator DPP4i’s according to the 95% credible intervals 
in the NMA, giving ICER estimates ranging from £3,937 to £16,727. Dapagliflozin 
had a 59% probability of being cost-effective versus DPP4i’s at a willingness-to-
pay threshold of £20,000 per QALY gained. ConClusions: Dapagliflozin as triple 
therapy in combination with met+SU was shown to be a cost-effective treatment 
option from a UK health care perspective for patients with T2DM who are inad-
equately controlled on met+SU.
PDB89
Cost-EffECtivEnEss of saxagliPtin ComParED to glP-1 analoguEs as 
an aDD-on to insulin in thE trEatmEnt of tyPE 2 DiaBEtEs mEllitus 
from a uk hEalth CarE PErsPECtivE
Charokopou M.1, Vioix H.2, Verheggen B.1, Eddowes L.A.3, Griffiths M.4, Gabriel Z.2, Tolley K.5, 
Sibartie M.2
1Pharmerit International, Rotterdam, The Netherlands, 2AstraZeneca UK Ltd., Luton, UK, 3Costello 
Medical Consulting Ltd., Cambridge, UK, 4Costello Medical Consulting, Cambridge, UK,  
5Tolley Health Economics Ltd., Buxton, Derbyshire, UK
objeCtives: To assess the cost-effectiveness of saxagliptin, a dipeptidyl pepti-
dase-4 inhibitor (DPP4i), compared to the glucagon-like peptide-1 (GLP-1) analogues, 
exenatide twice-daily or lixisenatide, when added to insulin (±metformin) for the 
treatment of patients with type 2 diabetes mellitus (T2DM) who are inadequately 
controlled on insulin. Methods: The validated CARDIFF diabetes model was used 
to conduct the analyses. Clinical inputs for the model were sourced from a system-
atic review and network meta-analysis (NMA), which found that the treatments 
were similarly effective at lowering HbA1c and that the GLP-1 analogues resulted 
in greater and clinically relevant weight loss. A UK health care perspective was 
used for costs, and quality-adjusted life years (QALYs) were calculated from util-
ity data sourced from the published literature. To assess uncertainty, univariate 
deterministic and multivariate probabilistic sensitivity analyses (PSA) were per-
formed. Results: Saxagliptin was found to dominate lixisenatide in the base case, 
being associated with lower costs (-£472 [95%CI: -1,378, -223]) and slightly more 
QALYs (0.010 [95%CI: -0.040, 0.076]). Saxagliptin was less costly (-£1,402 [95%CI: 
-£1,932, -£1,218]) and slightly less effective (-0.012 QALYs [95%CI: -0.054, 0.035]) than 
exenatide twice-daily. The lower costs associated with saxagliptin were primarily 
due to the lower drug acquisition costs. The estimated QALY differences were small 
and associated with the impact of weight reduction on health-related quality of 
life. Univariate sensitivity analyses demonstrated that the results were most sensi-
tive to varying the HbA1c treatment effect and the effect of saxagliptin on weight 
change. The PSA estimated that saxagliptin had a 70.4% and 34.3% probability of 
being dominant, and a 99.4% and 100% probability of being cost-saving compared to 
lixisenatide and exenatide twice-daily, respectively. ConClusions: Saxagliptin as 
add-on to insulin was shown to be a cost-saving treatment option from a UK health 
care perspective for patients with T2DM who are inadequately controlled on insulin.
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objeCtives: To conduct a systematic review of cost-effectiveness, cost-utility and 
cost-benefit studies of new inhibitors of DPP-4 for diabetes treatment versus other 
antidiabetics. Methods: We searched the CRD York, NICE Health Technology 
Assessment, Tufts CEA Registry, and MEDLINE (PubMed) databases, and grey litera-
ture through 2014 to identify cost-effectiveness, cost-utility and cost-benefit studies 
of new inhibitors of DPP-4 versus other antidiabetics for diabetes treatment. Three 
investigators independently reviewed all potentially relevant titles and abstracts (1st 
screening), and subsequently screened full-text articles (2nd screening), according to 
pre-established inclusion criteria. We restricted our sample to studies with a lifetime 
or near-lifetime horizon, and adopting either a societal or a health care perspective. 
The studies should be available as a full-text publication and published in English, 
French, Spanish, or Portuguese language. A critical appraisal of the methodology and 
reporting was performed using the 35item version of the BMJ checklist. Results: 
A total of 57 studies were identified. From these, 17 studies were accepted after the 
1st screening, of which 11 were accepted after the 2nd screening. All selected studies 
consisted in cost-utility analyses. Most studies were based on a single randomized 
trial per therapy. Saxagliptin was assessed in 6 studies, Sitagliptin in 4, and vilda-
gliptin in 1. Liraglutide was cost-effective versus sitagliptin as second line therapy 
(ranged from 12,164 to 27,289€ /QALY across countries). Saxagliptin (ranged from 
771 to 10,065 € /QALY across countries), Sitagliptin (ranged from 5,949 € /QALY to 
20,350 € /QALY across countries) and vildagliptin (ICER of 9,072 € / QALY in Portugal) 
were cost-effective versus sulfonylureas as second line therapy. ConClusions: 
According to commonly accepted thresholds, there is consistent evidence about the 
cost-effectiveness of DDP-4 inhibitors as second line therapy for diabetes type 2. 
Though, more evidence (including head-to-head) is necessary to define which DDP-4 
inhibitor is the most cost-effective.
and SU would generate substantial cost savings in France. Canagliflozin 300mg 
showed similar outcomes to liraglutide, suggesting that the treatments are similar 
in effectiveness, and is thus likely to be a highly cost-effective treatment option.
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objeCtives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. The model allows flexible layering of multiple interventions in order to 
determine the optimal combination of strategies for maximal cost-effectiveness. Our 
objective was to demonstrate the utility of the model for analysis of multiple inter-
ventions in different population sub-groups. Methods: A model of type-2 diabetes 
prevention was developed using a micro-simulation framework. Individual patients 
have simulated trajectories of metabolic factors such as BMI, HbA1c, systolic blood 
pressure and total cholesterol, and can be diagnosed with diabetes, cardiovascular 
disease, cancer, osteoarthritis or microvascular complications of diabetes over the 
course of a lifetime. Interventions targeting metabolic factors influence the likelihood 
of patients developing ill health and dying prematurely. Five interventions were cho-
sen for layering analyses: soft drinks taxation; retail policy; a workplace intervention; 
an educational intervention aimed at deprived individuals; and a diabetes screening 
programme followed by intensive intervention for high risk individuals. Eight dif-
ferent intervention combinations were modelled, using the assumption of either 
additive, synergistic or antagonistic effects in individuals subject to multiple interven-
tions. Results: All interventions generated cost-savings and QALY gains, with the 
screening intervention performing particularly well, followed by the soft drinks tax. 
Combining interventions results in roughly additive effects; this holds whether the 
layering is additive, synergistic or antagonistic due to the relatively low proportions 
of individuals subject to multiple interventions. Certain pairs of interventions were 
found to be almost as cost-effective as combining all five interventions, in particular, 
a soft drinks tax combined with a screening programme is likely to be one of the most 
cost-effective options. ConClusions: The SPHR Diabetes Model is a useful tool for 
analysing the cost-effectiveness of different diabetes prevention interventions, either 
singly or in combination. This will enable development of intervention strategies 
tailored to the needs of the target population.
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objeCtives: To explore the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, as monotherapy for the treatment of type 2 
diabetes mellitus (T2DM) that is inadequately controlled by diet and exercise alone 
in patients who are intolerant to metformin. Methods: The validated CARDIFF 
diabetes model was used. Clinical inputs for the model were sourced from a sys-
tematic review and network meta-analysis (NMA) in monotherapy. A UK health 
care perspective was used for costs, and quality-adjusted life years (QALYs) were 
calculated from utility data in the published literature. A range of assumptions to 
reflect potential clinical practice were utilised. Alterations to the HbA1c switching 
threshold and assumptions on weight extrapolation were considered, in order to 
investigate the impact of different profiles of weight change and longer-term evi-
dence for the maintenance of weight loss. The cost-effectiveness was reported as an 
incremental cost-effectiveness ratio (ICER). Results: When the model assumptions 
were varied around the HbA1c switching threshold and around the profile of main-
tenance of weight loss to better reflect clinical practice, the ICER point estimates 
ranged from £1,847 to £30,795. The lowest ICER point estimate was associated with 
an assumption of maintaining the weight differential that is created at treatment 
initiation, which is generated by the better weight profile of dapagliflozin compared 
to DPP4i, over the whole time horizon. The highest estimate arose when the weight 
differential was maintained for 2 years and there was a higher switching threshold 
for initiating insulin. ConClusions: Dapagliflozin monotherapy has potential as 
a cost-effective treatment option from a UK health care perspective for patients 
with T2DM who are intolerant to metformin and are inadequately controlled by 
diet and exercise alone, based upon a range of explored scenarios. This study also 
demonstrates the value of performing scenario analysis to inform decision-making.
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objeCtives: To assess the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, when used as triple oral therapy in combina-
tion with metformin and a sulphonylurea (met+SU) for the treatment of patients 
with type 2 diabetes mellitus (T2DM) who are inadequately controlled on met+SU 
alone. Methods: The validated CARDIFF diabetes model was used. Clinical 
inputs for the model were sourced from a systematic review and network meta-
analysis (NMA) in triple therapy that found clinically relevant differences between 
dapagliflozin and DPP4i’s. A UK health care perspective was used for costs, and 
